Most Xgeva (denosumab) side effects are tied to the drug’s activity in your body, which fades over four to five months after your last injection. The drug has a mean half-life of about 25 days, meaning it takes roughly that long for your blood levels to drop by half, and serum concentrations decline steadily over that four-to-five-month window. Common side effects like nausea, fatigue, and headache generally follow that same timeline, easing as the drug clears. A few effects, particularly low calcium levels and changes in bone turnover, can persist for six months or longer.
How Long Xgeva Stays in Your System
Xgeva is given as a subcutaneous injection, typically every four weeks. After each dose, blood levels of the drug rise and then gradually taper. The mean elimination half-life is 25.4 days, and measurable drug levels decline over a period of four to five months. This is the window during which side effects from a given dose are most likely to occur or persist.
Because the drug doesn’t bind permanently to bone the way some other bone-protecting medications do, its effects are reversible. Once it clears, the proteins it was blocking resume their normal activity. That reversibility is mostly good news for side effects, but it also creates a distinct rebound period that matters if you stop treatment (more on that below).
Common Side Effects and Their Duration
In clinical trials of patients with bone metastases from solid tumors, the most frequently reported side effects were fatigue or weakness (45% of patients), low phosphate levels (32%), nausea (31%), shortness of breath (21%), diarrhea (20%), low calcium (18%), headache (13%), and cough (15%). For patients with multiple myeloma, diarrhea (34%), nausea (32%), back pain (21%), and low calcium (16%) were among the most common. In giant cell tumor of bone, joint pain, back pain, limb pain, and musculoskeletal pain all appeared in more than 10% of patients.
The prescribing information does not give precise durations for individual side effects. In practice, symptoms like nausea, fatigue, headache, and diarrhea are usually worst in the days following an injection and tend to improve within one to two weeks. Because the drug’s concentration is highest shortly after injection, these everyday side effects are most noticeable early in each dosing cycle and fade as the drug level drops.
Musculoskeletal Pain
Bone, joint, and muscle pain deserve their own mention because they are among the most bothersome effects for many people on Xgeva. Joint pain, back pain, pain in the arms or legs, and general musculoskeletal pain are all listed as common side effects, especially in giant cell tumor patients. Post-marketing reports have also flagged severe musculoskeletal pain, and in some cases the pain returned when the drug was given again (a “positive rechallenge”), confirming the drug as the cause.
For most people, this pain is worst in the first week or two after an injection. If it recurs with every dose, that pattern typically continues for as long as treatment lasts and then resolves as the drug clears over the following months. Severe cases that prompted discontinuation have generally improved once the drug left the system, within that four-to-five-month clearance window.
Low Calcium: A Side Effect That Can Linger
Xgeva works by blocking a protein that activates bone-dissolving cells. When those cells slow down, less calcium gets released from bone into the bloodstream, which can drive calcium levels too low. This is called hypocalcemia, and it occurred in 16% to 18% of patients in clinical trials.
Low calcium from Xgeva is reversible once the drug is stopped, but the drug’s bone-suppressing effect lasts up to six months per dose. That means hypocalcemia can persist for the full duration of the drug’s action. Symptoms of low calcium include tingling in the fingers or around the mouth, muscle cramps or spasms, and in severe cases, heart rhythm changes. If you’re experiencing these, your care team will monitor your calcium and vitamin D levels and supplement as needed. The effect resolves as the drug clears, but close monitoring during those months is important.
Jaw Complications (Osteonecrosis)
Osteonecrosis of the jaw is a rare but serious complication where a section of jawbone becomes exposed and doesn’t heal normally. The risk is higher in cancer patients receiving Xgeva every four weeks compared to osteoporosis patients on lower doses. Because Xgeva suppresses bone remodeling, the jaw (which turns over bone quickly due to the stresses of chewing) is particularly vulnerable.
Unlike the drug itself, jaw osteonecrosis doesn’t simply resolve when the medication clears. Once a lesion develops, healing depends on the severity. After stopping denosumab, bone remodeling suppression lifts within about six months, which opens a window for healing. If surgery is needed, guidelines recommend waiting at least six to eight weeks after the procedure before restarting any bone-protecting drug, to allow soft tissue to close and mature. For some patients, full resolution of a jaw lesion takes considerably longer than six months, particularly if the area is extensive or if dental procedures triggered the problem.
What Happens When You Stop Xgeva
Stopping Xgeva creates a rebound effect that’s important to understand. Once the drug clears, bone-dissolving activity doesn’t just return to normal. It overshoots, rising above the level it was at before treatment started. In studies of postmenopausal women, markers of bone breakdown began climbing about three months after the drug was discontinued (roughly nine months after the last injection), peaked around six months after discontinuation, and took about 24 months to settle back to pre-treatment levels.
This rebound surge in bone turnover can cause rapid bone loss and, in some cases, multiple spontaneous vertebral fractures. The risk is significant enough that guidelines warn against stopping denosumab without a plan to transition to another bone-protecting therapy. If you and your doctor decide to stop Xgeva, the transition period requires careful management, often involving a switch to a different class of medication to prevent this rebound.
The rebound effect is not a “side effect” in the traditional sense. It’s a consequence of removing the drug’s protection. But it’s the reason many people who search for how long Xgeva’s effects last are asking: the drug itself clears in four to five months, yet the bone consequences of stopping can play out over one to two years.
Timeline Summary
- Days to weeks after injection: Common side effects like nausea, fatigue, headache, and diarrhea are typically strongest and then fade.
- Up to 6 months after last dose: Low calcium can persist for the full duration of the drug’s bone-suppressing activity. Musculoskeletal pain usually resolves within this window.
- 4 to 5 months after last dose: The drug itself is no longer detectable in the blood.
- 6 to 24 months after stopping: Bone turnover markers rebound above baseline, peaking around 6 months post-discontinuation and normalizing by roughly 24 months.
- Variable (months to years): Jaw osteonecrosis, if present, follows its own healing timeline depending on severity and treatment.